Literature DB >> 17724802

Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.

Alberto Pilotto1, Marilisa Franceschi, Gioacchino Leandro, Carlo Scarcelli, Luigi Piero D'Ambrosio, Francesco Paris, Vito Annese, Davide Seripa, Angelo Andriulli, Francesco Di Mario.   

Abstract

AIM: To compare efficacy and tolerability of four proton pump inhibitors (PPIs) commonly used in the short-term therapy of esophagitis in elderly patients.
METHODS: A total of 320 patients over 65 years with endoscopically diagnosed esophagitis were randomly assigned to one of the following treatments for 8 wk: (1) omeprazole 20 mg/d; (2) lansoprazole 30 mg/d; (3) pantoprazole 40 mg/d, or (4) rabeprazole 20 mg/d. Major symptoms, compliance, and adverse events were recorded. After 8 wk, endoscopy and clinical evaluation were repeated.
RESULTS: Per protocol and intention to treat healing rates of esophagitis were: omeprazole = 81.0% and 75.0%, lansoprazole = 90.7% (P = 0.143 vs omeprazole) and 85.0%, pantoprazole = 93.5% (P = 0.04 vs omeprazole) and 90.0% (P = 0.02 vs omeprazole), rabeprazole = 94.6% (P = 0.02 vs omeprazole) and 88.8% (P = 0.04 vs omeprazole). Dividing patients according to the grades of esophagitis, omeprazole was significantly less effective than the three other PPIs in healing grade 1 esophagitis (healing rates: 81.8% vs 100%, 100% and 100%, respectively, P = 0.012). Pantoprazole and rabeprazole (100%) were more effective vs omeprazole (89.6%, P = 0.0001) and lansoprazole (82.4%, P = 0.0001) in decreasing heartburn. Pantoprazole and rabeprazole (92.2% and 90.1%, respectively) were also more effective vs lansoprazole (75.0%, P < 0.05) in decreasing acid regurgitation. Finally, pantoprazole and rabeprazole (95.2% and 100%) were also more effective vs lansoprazole (82.6%, P < 0.05) in decreasing epigastric pain.
CONCLUSION: In elderly patients, pantoprazole and rabeprazole were significantly more effective than omeprazole in healing esophagitis and than omeprazole or lansoprazole in improving symptoms. H pylori infection did not influence the healing rates of esophagitis after a short-term treatment with PPI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724802      PMCID: PMC4611579          DOI: 10.3748/wjg.v13.i33.4467

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  Influence of Helicobacter pylori infection on severity of oesophagitis and response to therapy in the elderly.

Authors:  A Pilotto; M Franceschi; G Leandro; M Rassu; L Bozzola; G Valerio; F Di Mario
Journal:  Dig Liver Dis       Date:  2002-05       Impact factor: 4.088

Review 2.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Esophagitis is a major cause of upper gastrointestinal hemorrhage in the elderly.

Authors:  J Zimmerman; V Shohat; E Tsvang; R Arnon; R Safadi; D Wengrower
Journal:  Scand J Gastroenterol       Date:  1997-09       Impact factor: 2.423

4.  Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.

Authors:  S J Edwards; T Lind; L Lundell
Journal:  Aliment Pharmacol Ther       Date:  2001-11       Impact factor: 8.171

Review 5.  Recent advances in the treatment of GERD in the elderly: focus on proton pump inhibitors.

Authors:  A Pilotto; M Franceschi; F Paris
Journal:  Int J Clin Pract       Date:  2005-10       Impact factor: 2.503

6.  Clinical features of reflux esophagitis in older people: a study of 840 consecutive patients.

Authors:  Alberto Pilotto; Marilisa Franceschi; Gioacchino Leandro; Carlo Scarcelli; Luigi P D'Ambrosio; Davide Seripa; Francesco Perri; Valeria Niro; Francesco Paris; Angelo Andriulli; Francesco Di Mario
Journal:  J Am Geriatr Soc       Date:  2006-10       Impact factor: 5.562

7.  Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis.

Authors:  V K Sharma; G I Leontiadis; C W Howden
Journal:  Aliment Pharmacol Ther       Date:  2001-02       Impact factor: 8.171

8.  Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.

Authors:  J J Caro; M Salas; A Ward
Journal:  Clin Ther       Date:  2001-07       Impact factor: 3.393

9.  Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.

Authors:  F Pace; V Annese; A Prada; A Zambelli; S Casalini; P Nardini; G Bianchi Porro
Journal:  Dig Liver Dis       Date:  2005-10       Impact factor: 4.088

10.  Hiatus hernia in gastroesophageal reflux disease.

Authors:  B Kaul; H Petersen; H E Myrvold; K Grette; P Røysland; T Halvorsen
Journal:  Scand J Gastroenterol       Date:  1986-01       Impact factor: 2.423

View more
  5 in total

Review 1.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

Review 2.  Guide to the use of proton pump inhibitors in adult patients.

Authors:  Vandana Boparai; Jaishree Rajagopalan; George Triadafilopoulos
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Claudine M Baldwin; Susan J Keam
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

4.  Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Meta-Analysis and GRADE system.

Authors:  Chao Zhang; Joey S W Kwong; Rui-Xia Yuan; Hao Chen; Chang Xu; Yi-Pin Wang; Gong-Li Yang; Jin-Zhu Yan; Le Peng; Xian-Tao Zeng; Hong Weng; Jie Luo; Yu-Ming Niu
Journal:  Sci Rep       Date:  2017-01-19       Impact factor: 4.379

Review 5.  Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis.

Authors:  X M Xia; H Wang
Journal:  Gastroenterol Res Pract       Date:  2013-09-09       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.